EC
ALLO icon

EntryPoint Capital’s Allogene Therapeutics ALLO Stock Holding History

EntryPoint Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-92,752
Closed -$216K – 624
2024
Q2 		$216K Buy
92,752
+62,937
+211% +$186K 0.1% 366
2024
Q1 		$133K Sell
29,815
-8,108
-21% -$33.8K 0.12% 274
2023
Q4 		$122K Buy
+37,923
New +$108K 0.12% 278

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EntryPoint Capital's ALLO Position: Q3 2024 in Review

EntryPoint Capital sold out of Allogene Therapeutics (ALLO) in Q3 2024, closing a stake of 92,752 shares — an estimated $216K sold.

EntryPoint Capital first reported a position in ALLO in Q4 2023 and held it in 3 quarters. The position peaked at $216K in Q2 2024. 156 funds tracked by Wall St. Rank hold ALLO as of Q3 2024.

  • EntryPoint Capital reported no remaining Allogene Therapeutics position as of Q3 2024 after selling out during the quarter.
  • EntryPoint Capital sold 92,752 Allogene Therapeutics shares in Q3 2024, an estimated $216K.
  • EntryPoint Capital first reported a position in Allogene Therapeutics in Q4 2023 and held it in 3 quarters.
  • EntryPoint Capital's Allogene Therapeutics position peaked at $216K in Q2 2024.
  • 156 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.